<DOC>
	<DOCNO>NCT01381523</DOCNO>
	<brief_summary>The goal study measure medical resource utilization , treatment pattern , cost 1 . ) triptan-naïve patient new pharmacy claim combination treatment sumatriptan naproxen sodium ( SumaRT/Nap ) single-entity triptan 2 . ) patient switch one triptan either SumaRT/Nap different single-entity triptan . The analysis compare mean number prescription tablet use ( include triptans , NSAIDs , opioids , ergot ) migraine-specific medical resource utilization/costs pharmacy cost incur health plan member switch SumaRT/Nap single-entity triptan . The null hypothesis triptan-naïve analysis difference observe resource utilization cost incur patient treat SumaRT/Nap treat single-entity triptan . The test hypothesis one group incur significantly few cost and/or significantly low health care utilization . For triptan switch analysis , null hypothesis difference observe cost health care utilization triptan patient switch SumaRT/Nap compare switch new triptan . The test hypothesis one treatment group experience significantly low cost and/or low health care utilization . The source data analysis Lifelink Health Plan Claims Database ( own IMS Health , Inc ) . This claim database include 60 million covered life . In addition inpatient outpatient record , database include standard mail-order pharmacy claim pay charge amount date service . Data July 1 , 2008 December 31 , 2009 ( study period ) use conduct retrospective analysis . Patients least one pharmacy claim SumaRT/Nap January 1 , 2009 June 30 , 2009 ( enrollment period ) identify . The date first SumaRT/Nap pharmacy claim index date patient . Each patient propensity score match oral triptan patient base follow pre-index covariates : age ; gender ; payer ; geographic region ; average monthly number tablet triptans , NSAIDs , opioids ; average number hospitalization , emergency department visit , physician visit month immediately precede index date well mean number hospitalization , emergency department visit , physician visit 5-month pre-index period . SumaRT/Nap patient single-entity match control pharmacy claim triptans prior index date analyze triptan naïve group , SumaRT/Nap patient single-entity match control switch new triptan analyze switch analysis .</brief_summary>
	<brief_title>A Combination Product Sumatriptan Naproxen Sodium Versus Single-entity Oral Triptans : An Analysis Real World Data</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<criteria>Patients age 18 64 year Patients continuous health plan eligibility 6month preindex period followup period Patients triptan switch analysis must least one pharmacy claim oral triptan 6 month , preindex period Patients pharmacy claim nasal triptan time study period Patients pharmacy claim one type oral triptan index date Patients singleentity oral triptan study group pharmacy claim SumaRT/Nap 6month followup period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>resource utilization</keyword>
	<keyword>naproxen sodium</keyword>
	<keyword>cost cost analysis</keyword>
	<keyword>triptan</keyword>
	<keyword>migraine</keyword>
</DOC>